In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proposed CREST-2 Trial Will Compare Drug Treatment With Revascularization In Carotid Artery Disease

Executive Summary

The trial could underscore the cost effectiveness of standalone drug therapy in treating some patients with carotid atherosclerosis, particularly with the blockbuster anticoagulant Plavix losing its patent protection this year and generics on the way.

You may also be interested in...



US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.

Drug Pricing Policies Attached To Surprise Medical Billing Legislation

Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.

Topics

Related Companies

UsernamePublicRestriction

Register

PS054145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel